Mirati Therapeutics Inc (MRTX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MRTX Annual Balance Sheets →
This balance sheet overview for Mirati Therapeutics Inc spans from Sep 30 2022 to Sep 30 2023, showing how the company's assets, liabilities, and equity have evolved across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent258.72
Marketable Securities, Current SH717.72
Cash & Short-term Investments975.00
Accounts receivable14.65
Inventories20.16
Other Current Assets0.00
Prepaid Expense And Other Assets Current24.84
Total Current Assets1,036.08
Equipment/Property/Plant Net16.05
Intangible Assets14.14
Long-term investments3.56
Other Assets, Noncurrent25.00
Operating Lease Right Of Use Asset35.07
Total Assets1,129.71
Liabilities
Accounts Payable AC37.96
Accrued Liabilities AC99.42
Total Current Liabilities137.38
Total Long-term Debt0.00
Other liabilities, Noncurrent45.86
Operating Lease Liability Noncurrent42.20
Total Liabilities183.24
Stockholders' Equity
Common Stock Value0.07
Additional Paid In Capital Common Stock3,924.24
Retained Earnings / Accumulated Deficit-2,976.29
Other Equity-1.55
Common Stockholder's Equity946.47
Total Stockholder's Equity946.47
Liabilities & Stockholder's Equity1,129.71
4 historic quarters locked

Sign in to unlock the full Mirati Therapeutics Inc balance sheet history.

About Mirati Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001628280-23-036875

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.